NIPT 21T (Trisomy 21 risk)

The test examines embryonic-placental cell-free DNA isolated from maternal plasma. The risk of a genetic disorder in the child is assessed. The study allows for the suspicion of certain disorders and syndromes and then, by being aware of them, to conduct timely treatment for the born child. It should be taken into account that this is a screening test, meaning a diagnosis cannot be made based on its results. It assesses the probability of chromosomal pathologies but does not allow for their definitive diagnosis even if a high risk is identified. The result of this test is not a diagnosis, but only a statistical probability figure. The test is performed from the 10th week of pregnancy in the absence of ultrasound signs of chromosomal pathology. The gestational age must be established based on ultrasound data. Prenatal genetic testing assesses the risk of chromosomal anomalies. If there is a risk of disorders, one can be prepared for the diagnosis and take care in advance to ensure specialized support and medical care for their child. With modern medical capabilities, a sufficiently high quality of life is possible for many congenital pathologies. Detection of an increased risk of developmental defects in the child is not a diagnosis. False-positive results are possible. Limitations of the method: - aneuploidies for other autosomes (chromosomes) are not determined; - chromosomal anomalies or chromosomal mosaicism in the mother; - gestational age less than 10 weeks at the time of blood collection for the study; - singleton pregnancy that began as a twin pregnancy ("vanishing twin"); - blood transfusion within the last 3 months; - organ, bone marrow, or stem cell transplantation in the past (in these cases, there is an increased risk of a false test result); - presence of an oncological disease; - in pregnant women with obesity, the concentration of the fetal DNA fraction is reduced due to a larger volume of circulating blood, which may lead to false results.

Within 15 days